Transcatheter aortic valve replacement in patients with cirrhosis

Kevin L. Greason, Verghese Mathew, Russel H. Wiesner, Rakesh M. Suri, Charanjit S. Rihal

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background Patients with cirrhosis who undergo cardiac operation with extracorporeal circulation are at high risk for operative morbidity and mortality. Transcatheter aortic valve replacement (TAVR) can obviate the need for cardiopulmonary bypass and may reduce operative morbidity in comparison to standard aortic valve replacement (SAVR) in select patients. Methods Review of 18 patients with aortic valve stenosis and cirrhosis treated with TAVR (n = 6) or SAVR (n = 12). Patient age was 71 years (58 to 83) and STS Predicted Risk of Mortality was 3.2% (0.7 to 12.3). There were 15 males (83%). Child-Turcotte-Pugh stage was A in 10 patients (56%), B in four (22%), and C in two (11%); the median MELD score was nine (7 to 14). Results TAVR was successful in all patients without the need for mechanical or cardiopulmonary bypass support. Blood transfusion occurred in four patients (67%) in the TAVR group and in the entire SAVR group. No deaths occurred in the TAVR group, and two (17%) occurred in the SAVR group. Operative complications occurred in two patients (33%) in TAVR group and in eight (67%) in the SAVR group. Hospital stay was five days (3 to 10) in the TAVR group and six (3 to 38) in the SAVR group. All TAVR patients were alive at last follow-up of 219 days (29 to 723), while only five were alive in the SAVR group at 228 days (36 to 719). Conclusions Our initial experience with TAVR in patients with cirrhosis is encouraging. The technique may be a viable alternative to SAVR in this high-risk subset of patients. doi: 10.1111/jocs.12177 (J Card Surg 2013;28:492-495)

Original languageEnglish (US)
Pages (from-to)492-495
Number of pages4
JournalJournal of Cardiac Surgery
Volume28
Issue number5
DOIs
StatePublished - Sep 2013

Fingerprint

Fibrosis
Aortic Valve
Cardiopulmonary Bypass
Transcatheter Aortic Valve Replacement
Morbidity
Extracorporeal Circulation
Mortality
Aortic Valve Stenosis
Blood Transfusion
Length of Stay

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

Greason, K. L., Mathew, V., Wiesner, R. H., Suri, R. M., & Rihal, C. S. (2013). Transcatheter aortic valve replacement in patients with cirrhosis. Journal of Cardiac Surgery, 28(5), 492-495. https://doi.org/10.1111/jocs.12177

Transcatheter aortic valve replacement in patients with cirrhosis. / Greason, Kevin L.; Mathew, Verghese; Wiesner, Russel H.; Suri, Rakesh M.; Rihal, Charanjit S.

In: Journal of Cardiac Surgery, Vol. 28, No. 5, 09.2013, p. 492-495.

Research output: Contribution to journalArticle

Greason, KL, Mathew, V, Wiesner, RH, Suri, RM & Rihal, CS 2013, 'Transcatheter aortic valve replacement in patients with cirrhosis', Journal of Cardiac Surgery, vol. 28, no. 5, pp. 492-495. https://doi.org/10.1111/jocs.12177
Greason, Kevin L. ; Mathew, Verghese ; Wiesner, Russel H. ; Suri, Rakesh M. ; Rihal, Charanjit S. / Transcatheter aortic valve replacement in patients with cirrhosis. In: Journal of Cardiac Surgery. 2013 ; Vol. 28, No. 5. pp. 492-495.
@article{420f5b4c35a2477caf6e38474216629c,
title = "Transcatheter aortic valve replacement in patients with cirrhosis",
abstract = "Background Patients with cirrhosis who undergo cardiac operation with extracorporeal circulation are at high risk for operative morbidity and mortality. Transcatheter aortic valve replacement (TAVR) can obviate the need for cardiopulmonary bypass and may reduce operative morbidity in comparison to standard aortic valve replacement (SAVR) in select patients. Methods Review of 18 patients with aortic valve stenosis and cirrhosis treated with TAVR (n = 6) or SAVR (n = 12). Patient age was 71 years (58 to 83) and STS Predicted Risk of Mortality was 3.2{\%} (0.7 to 12.3). There were 15 males (83{\%}). Child-Turcotte-Pugh stage was A in 10 patients (56{\%}), B in four (22{\%}), and C in two (11{\%}); the median MELD score was nine (7 to 14). Results TAVR was successful in all patients without the need for mechanical or cardiopulmonary bypass support. Blood transfusion occurred in four patients (67{\%}) in the TAVR group and in the entire SAVR group. No deaths occurred in the TAVR group, and two (17{\%}) occurred in the SAVR group. Operative complications occurred in two patients (33{\%}) in TAVR group and in eight (67{\%}) in the SAVR group. Hospital stay was five days (3 to 10) in the TAVR group and six (3 to 38) in the SAVR group. All TAVR patients were alive at last follow-up of 219 days (29 to 723), while only five were alive in the SAVR group at 228 days (36 to 719). Conclusions Our initial experience with TAVR in patients with cirrhosis is encouraging. The technique may be a viable alternative to SAVR in this high-risk subset of patients. doi: 10.1111/jocs.12177 (J Card Surg 2013;28:492-495)",
author = "Greason, {Kevin L.} and Verghese Mathew and Wiesner, {Russel H.} and Suri, {Rakesh M.} and Rihal, {Charanjit S.}",
year = "2013",
month = "9",
doi = "10.1111/jocs.12177",
language = "English (US)",
volume = "28",
pages = "492--495",
journal = "Journal of Cardiac Surgery",
issn = "0886-0440",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Transcatheter aortic valve replacement in patients with cirrhosis

AU - Greason, Kevin L.

AU - Mathew, Verghese

AU - Wiesner, Russel H.

AU - Suri, Rakesh M.

AU - Rihal, Charanjit S.

PY - 2013/9

Y1 - 2013/9

N2 - Background Patients with cirrhosis who undergo cardiac operation with extracorporeal circulation are at high risk for operative morbidity and mortality. Transcatheter aortic valve replacement (TAVR) can obviate the need for cardiopulmonary bypass and may reduce operative morbidity in comparison to standard aortic valve replacement (SAVR) in select patients. Methods Review of 18 patients with aortic valve stenosis and cirrhosis treated with TAVR (n = 6) or SAVR (n = 12). Patient age was 71 years (58 to 83) and STS Predicted Risk of Mortality was 3.2% (0.7 to 12.3). There were 15 males (83%). Child-Turcotte-Pugh stage was A in 10 patients (56%), B in four (22%), and C in two (11%); the median MELD score was nine (7 to 14). Results TAVR was successful in all patients without the need for mechanical or cardiopulmonary bypass support. Blood transfusion occurred in four patients (67%) in the TAVR group and in the entire SAVR group. No deaths occurred in the TAVR group, and two (17%) occurred in the SAVR group. Operative complications occurred in two patients (33%) in TAVR group and in eight (67%) in the SAVR group. Hospital stay was five days (3 to 10) in the TAVR group and six (3 to 38) in the SAVR group. All TAVR patients were alive at last follow-up of 219 days (29 to 723), while only five were alive in the SAVR group at 228 days (36 to 719). Conclusions Our initial experience with TAVR in patients with cirrhosis is encouraging. The technique may be a viable alternative to SAVR in this high-risk subset of patients. doi: 10.1111/jocs.12177 (J Card Surg 2013;28:492-495)

AB - Background Patients with cirrhosis who undergo cardiac operation with extracorporeal circulation are at high risk for operative morbidity and mortality. Transcatheter aortic valve replacement (TAVR) can obviate the need for cardiopulmonary bypass and may reduce operative morbidity in comparison to standard aortic valve replacement (SAVR) in select patients. Methods Review of 18 patients with aortic valve stenosis and cirrhosis treated with TAVR (n = 6) or SAVR (n = 12). Patient age was 71 years (58 to 83) and STS Predicted Risk of Mortality was 3.2% (0.7 to 12.3). There were 15 males (83%). Child-Turcotte-Pugh stage was A in 10 patients (56%), B in four (22%), and C in two (11%); the median MELD score was nine (7 to 14). Results TAVR was successful in all patients without the need for mechanical or cardiopulmonary bypass support. Blood transfusion occurred in four patients (67%) in the TAVR group and in the entire SAVR group. No deaths occurred in the TAVR group, and two (17%) occurred in the SAVR group. Operative complications occurred in two patients (33%) in TAVR group and in eight (67%) in the SAVR group. Hospital stay was five days (3 to 10) in the TAVR group and six (3 to 38) in the SAVR group. All TAVR patients were alive at last follow-up of 219 days (29 to 723), while only five were alive in the SAVR group at 228 days (36 to 719). Conclusions Our initial experience with TAVR in patients with cirrhosis is encouraging. The technique may be a viable alternative to SAVR in this high-risk subset of patients. doi: 10.1111/jocs.12177 (J Card Surg 2013;28:492-495)

UR - http://www.scopus.com/inward/record.url?scp=84883886261&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883886261&partnerID=8YFLogxK

U2 - 10.1111/jocs.12177

DO - 10.1111/jocs.12177

M3 - Article

C2 - 23899420

AN - SCOPUS:84883886261

VL - 28

SP - 492

EP - 495

JO - Journal of Cardiac Surgery

JF - Journal of Cardiac Surgery

SN - 0886-0440

IS - 5

ER -